Komipharm International Co Ltd
041960
Company Profile
Business description
Komipharm International Co Ltd is involved in the healthcare sector based in Korea. Its core business includes development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The company produces its products under two divisions: veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle. The other division is made up of veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis and swine erysipelas.
Contact
1236-6 Jungwang-Dong
SihungGyeonggi429-450
KORT: +82 314986104
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
165
Stocks News & Analysis
stocks
SK Hynix Earnings: We raise fair value estimate on strong AI memory demand
Shares jumped 9% after earnings, as stronger AI memory prices boosted the chipmaker’s outlook.
stocks
Meta shares are down 12% since earnings. Is the stock a buy?
Concerns about equity sales to finance AI investments have pressured shares.
stocks
SpaceX earnings: We raise our fair value estimate on scaling data centres, but is the stock a buy?
AI data center revenue is growing fast, but questions about durability remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,012.60 | 41.20 | 0.46% |
| CAC 40 | 7,970.00 | 83.04 | 1.05% |
| DAX 40 | 26,039.68 | 335.66 | 1.31% |
| Dow JONES (US) | 52,200.77 | 274.33 | -0.52% |
| FTSE 100 | 10,722.07 | 27.57 | 0.26% |
| HKSE | 22,958.65 | 136.18 | -0.59% |
| NASDAQ | 26,135.07 | 414.79 | -1.56% |
| Nikkei 225 | 64,659.47 | 705.28 | 1.10% |
| NZX 50 Index | 13,710.17 | 18.84 | 0.14% |
| S&P 500 | 7,701.70 | 42.28 | -0.55% |
| S&P/ASX 200 | 8,891.80 | 44.50 | 0.50% |
| SSE Composite Index | 3,651.43 | 30.04 | -0.82% |